| Literature DB >> 30784897 |
Diomira Luongo1, Roberta Bonavita1, Stefano Rossi1, Vera Rotondi Aufiero1, Nicoletta Rosaria Feliciello1, Francesco Maurano1, Gaetano Iaquinto2, Giuseppe Mazzarella1, Mauro Rossi3.
Abstract
Enzymatic transamidation of wheat gliadin by microbial transglutaminase inhibits IFN-γ secretion by intestinal T cell lines from celiac disease (CD) patients. Here, we analysed its effects on intestinal biopsies from CD patients and studied the underlying mechanisms in HLA-DQ8 transgenic (tg) mice, a model of T-cell mediated gluten sensitivity. In vitro challenge with a soluble form of transamidated gliadin (spf) upregulated IL-10 transcript levels in human biopsy samples. Furthermore, the ratio of IL-10/IFN-γ transcripts was significantly increased following treatment with spf. In DQ8 tg mice, recall responses in vitro in the presence of dendritic cells pulsed with transamidated gliadin showed that gliadin-specific CD4+ T cells did not produce IFN-γ at any tested dose. On the contrary, spf-specific CD4+ T cells still secreted IFN-γ, but they also produced significant levels of IL-10 with both native and transamidated gliadin. Interestingly, this anti-inflammatory activity was restricted to a specific reverse-phase high-pressure liquid chromatography (RP-HPLC) fraction encompassing α-gliadins. These findings suggested an ability of transamidated gliadin to revert, as well as to prevent, the inflammatory phenotype triggered by native gliadin. This property was intrinsically associated with specific components of the α-gliadin fraction.Entities:
Keywords: Celiac disease; Gliadin; Immunomodulation; Small intestine; Transamidation
Mesh:
Substances:
Year: 2019 PMID: 30784897 DOI: 10.1016/j.cyto.2019.02.004
Source DB: PubMed Journal: Cytokine ISSN: 1043-4666 Impact factor: 3.861